{"id":3728,"date":"2026-10-09T14:46:16","date_gmt":"2026-10-09T14:46:16","guid":{"rendered":"https:\/\/nhdbio.com\/?p=3728"},"modified":"2026-10-10T07:26:16","modified_gmt":"2026-10-10T07:26:16","slug":"cagrisema-tirzepatide-reimaginar5-comparacion-directa-explicada","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","title":{"rendered":"CagriSema vs Tirzepatida: \u00bfQu\u00e9 compar\u00f3 realmente REIMAGINE 5?"},"content":{"rendered":"<p>Un titular afirma que un tratamiento produjo m\u00e1s p\u00e9rdida de peso que otro. Antes de llamarlo ganador, haz una pregunta m\u00e1s sencilla: \u00bfqui\u00e9nes participaron y qu\u00e9 se compar\u00f3 exactamente?<\/p>\n<p>El anuncio de REIMAGINE 2026 de septiembre de 5 es \u00fatil porque los dos tratamientos se compararon dentro del mismo ensayo. Pero el resultado sigue perteneciendo a los grupos y dosis concretos evaluados.<\/p>\n<h2>El resultado, con su contexto<\/h2>\n<p>Novo Nordisk anunci\u00f3 estos resultados principales el 21 de septiembre de 2026. REIMAGINE 5 incluy\u00f3 a adultos con diabetes tipo 2 con control inadecuado mediante metformina, un inhibidor de SGLT2, o ambos. El ensayo compar\u00f3 CagriSema 1.0 mg\/1.0 mg con tirzepatida 5 mg durante 60 semanas.<\/p>\n<table>\n<thead>\n<tr>\n<th>Cambio notificado a las 60 semanas<\/th>\n<th>CagriSema<\/th>\n<th>Tirzepatida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Reducci\u00f3n del peso corporal, estimando de eficacia<\/td>\n<td>12.4%<\/td>\n<td>9.1%<\/td>\n<\/tr>\n<tr>\n<td>Reducci\u00f3n de HbA1c<\/td>\n<td>1.71 puntos porcentuales<\/td>\n<td>1.67 puntos porcentuales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>La compa\u00f1\u00eda report\u00f3 una mayor reducci\u00f3n de peso con CagriSema y no inferioridad para la reducci\u00f3n de HbA1c. La no inferioridad no es una afirmaci\u00f3n de que el control de la glucosa fuera superior. CagriSema combina cagrilintida y semaglutida y era un tratamiento en investigaci\u00f3n en este anuncio.<\/p>\n<h2>\u00bfQu\u00e9 significa una diferencia de 3.3 puntos?<\/h2>\n<p>Subtracting 9.1 from 12.4 gives 3.3 percentage points. Calling that \u201c3.3% more effective\u201d would leave the reader unsure what the percentage refers to.<\/p>\n<p>Como ejemplo aritm\u00e9tico, si dos personas hipot\u00e9ticas comenzaran cada una en 100 kg, reducciones del 12.4% y del 9.1% equivaldr\u00edan a 12.4 kg y 9.1 kg. Estos son pesos iniciales inventados para explicar el c\u00e1lculo, no resultados individuales del ensayo ni predicciones.<\/p>\n<h2>Por qu\u00e9 importan las dosis probadas<\/h2>\n<p>Esta comparaci\u00f3n no abarca todas las dosis posibles de ninguno de los dos tratamientos. Tampoco establece el resultado en personas sin diabetes. Un t\u00edtulo cuidadoso nombra el ensayo en lugar de declarar un ganador universal.<\/p>\n<p>Piense en comparar dos coches en una misma ruta. La prueba puede decirle qu\u00e9 ocurri\u00f3 en esa ruta, bajo esas condiciones. No puede responder a todas las preguntas sobre todas las carreteras.<\/p>\n<h2>El peso y la glucosa son resultados distintos<\/h2>\n<p>La HbA1c es una medida de an\u00e1lisis de sangre que se usa para evaluar los niveles de glucosa a m\u00e1s largo plazo. El peso corporal mide algo diferente. Un resultado m\u00e1s s\u00f3lido en un desenlace no significa autom\u00e1ticamente un resultado m\u00e1s s\u00f3lido en el otro.<\/p>\n<p>Del mismo modo, el estimando de eficacia describe una forma concreta de estimar el efecto del tratamiento. Debe mantenerse vinculado a la cifra de peso cuando se cita ese n\u00famero. Omitirlo dificulta la interpretaci\u00f3n de las comparaciones con estudios analizados de forma diferente.<\/p>\n<h2>\u00bfQu\u00e9 deber\u00edan buscar los lectores a continuaci\u00f3n?<\/h2>\n<p>Las noticias de titulares ofrecen una visi\u00f3n general temprana. Un informe detallado deber\u00eda permitir a los lectores examinar el n\u00famero de participantes, los resultados faltantes, la incertidumbre, las discontinuaciones del tratamiento y los eventos adversos. Estos detalles son necesarios antes de convertir dos porcentajes en un juicio m\u00e1s amplio sobre beneficio y tolerabilidad.<\/p>\n<h2>Materiales relacionados para investigaci\u00f3n de laboratorio<\/h2>\n<p>El <a href=\"https:\/\/nhdbio.com\/es\/productos\/cagrilintida\/\">Cagrilintida<\/a> y <a href=\"https:\/\/nhdbio.com\/es\/productos\/tirzepatida\/\">Tirzepatida<\/a> las p\u00e1ginas identifican familias de cat\u00e1logo relacionadas. NHD tambi\u00e9n enumera un <a href=\"https:\/\/nhdbio.com\/es\/productos\/mezcla-de-cagrilintida-y-semaglutida\/\">Cagrilintide\u2013Semaglutide blend<\/a>; ese listado no es evidencia de que reproduzca el medicamento del ensayo ni su formulaci\u00f3n.<\/p>\n<p>Para una consulta, ind\u00edcanos el nombre del material, la cantidad y la prueba de laboratorio prevista. Pregunta qu\u00e9 registros de identidad, pureza y otros registros anal\u00edticos est\u00e1n disponibles para la variante seleccionada. <a href=\"https:\/\/nhdbio.com\/es\/cita\/\">Solicita informaci\u00f3n del producto a NHD<\/a>.<\/p>\n<p>Los medicamentos utilizados en estos ensayos no son intercambiables con los materiales del cat\u00e1logo de NHD. Los hallazgos de los ensayos no establecen efectos cl\u00ednicos, equivalencia de formulaci\u00f3n ni la calidad de un lote de NHD.<\/p>\n<h2>Leer m\u00e1s<\/h2>\n<p><a href=\"https:\/\/nhdbio.com\/es\/cagrisema-redefinir1-cambio-de-peso-combinacion-explicada\/\">Explora la explicaci\u00f3n de la investigaci\u00f3n relacionada<\/a>.<\/p>\n<h2>Fuente y revisi\u00f3n editorial<\/h2>\n<p><a href=\"https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=916774\">Anuncio de Novo Nordisk, 21 de septiembre de 2026<\/a>. Consultado el 9 de octubre de 2026. Este art\u00edculo explica un anuncio de empresa; no es una revisi\u00f3n por pares independiente. Se completaron comprobaciones de fuentes y legibilidad asistidas por IA antes de la publicaci\u00f3n.<\/p>\n<p>Los materiales del cat\u00e1logo NHD son para investigaci\u00f3n, desarrollo y fabricaci\u00f3n en laboratorio, no para uso humano o veterinario. Este art\u00edculo no proporciona instrucciones de tratamiento ni dosificaci\u00f3n.<\/p>","protected":false},"excerpt":{"rendered":"<p>El anuncio de REIMAGINE de septiembre de 2026 5 inform\u00f3 una reducci\u00f3n de peso de 12.4% frente a 9.1%. Comprenda la poblaci\u00f3n, las dosis probadas y los l\u00edmites de la comparaci\u00f3n.<\/p>","protected":false},"author":1,"featured_media":3925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320,321,370","pim_article_type":"Research news explained","pim_evidence_level":"Company-reported results; study-specific limitations retained","pim_reviewer":"Codex AI editorial","pim_reviewed_date":"2026-10-09","pim_editorial_note":"AI-assisted source and readability checks, not independent peer review.","pim_review_status":"reviewed","pim_review_reason":"Primary sources and corrections checked; study populations and limitations retained; product-family links and enquiry paths reviewed; plain-language edit completed.","pim_creation_method":"AI-assisted writing","pim_sources":"[]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-3728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?<\/title>\n<meta name=\"description\" content=\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/cagrisema-tirzepatide-reimaginar5-comparacion-directa-explicada\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\" \/>\n<meta property=\"og:description\" content=\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/cagrisema-tirzepatide-reimaginar5-comparacion-directa-explicada\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T14:46:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-10T07:26:16+00:00\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\",\"datePublished\":\"2026-10-09T14:46:16+00:00\",\"dateModified\":\"2026-10-10T07:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"},\"wordCount\":562,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\",\"name\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"datePublished\":\"2026-10-09T14:46:16+00:00\",\"dateModified\":\"2026-10-10T07:26:16+00:00\",\"description\":\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Editorial comic illustration: CagriSema vs Tirzepatide. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CagriSema vs Tirzepatida: \u00bfQu\u00e9 compar\u00f3 realmente REIMAGINE 5?","description":"El anuncio de REIMAGINE de septiembre de 2026 5 inform\u00f3 una reducci\u00f3n de peso de 12.4% frente a 9.1%. Comprenda la poblaci\u00f3n, las dosis probadas y los l\u00edmites de la comparaci\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/cagrisema-tirzepatide-reimaginar5-comparacion-directa-explicada\/","og_locale":"es_ES","og_type":"article","og_title":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?","og_description":"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.","og_url":"https:\/\/nhdbio.com\/es\/cagrisema-tirzepatide-reimaginar5-comparacion-directa-explicada\/","og_site_name":"NHD","article_published_time":"2026-10-09T14:46:16+00:00","article_modified_time":"2026-10-10T07:26:16+00:00","author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?","datePublished":"2026-10-09T14:46:16+00:00","dateModified":"2026-10-10T07:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"},"wordCount":562,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","articleSection":["Published Study Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","url":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","name":"CagriSema vs Tirzepatida: \u00bfQu\u00e9 compar\u00f3 realmente REIMAGINE 5?","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","datePublished":"2026-10-09T14:46:16+00:00","dateModified":"2026-10-10T07:26:16+00:00","description":"El anuncio de REIMAGINE de septiembre de 2026 5 inform\u00f3 una reducci\u00f3n de peso de 12.4% frente a 9.1%. Comprenda la poblaci\u00f3n, las dosis probadas y los l\u00edmites de la comparaci\u00f3n.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","width":1536,"height":1024,"caption":"Editorial comic illustration: CagriSema vs Tirzepatide. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/3728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=3728"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/3728\/revisions"}],"predecessor-version":[{"id":3732,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/3728\/revisions\/3732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/3925"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=3728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=3728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=3728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}